Metagenomi Announces Participation in March 2023 Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced that it will participate in two upcoming investor conferences.

  • TD Cowen's 43rd Annual Health Care Conference
    In-Person
    March 7, 2023
    Participants: Brian C. Thomas, PhD, CEO and Founder, Metagenomi; Jian Irish, PhD, MBA, President and COO, Metagenomi; Simon Harnest, CIO and SVP, Strategy, Metagenomi
  • Barclays Global Healthcare Conference
    In-person
    March 16, 2023
    Participant: Simon Harnest, CIO and SVP, Strategy, Metagenomi

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://​metageno​mi​.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005538/en/

Contacts

Investor:
Simon Harnest
CIO, SVP Strategy
simon@metagenomi.co
(917) 403-1051

Media:
Ashlye Hodge
Communications Manager
ashlye@metagenomi.co
(510) 734-4409

Source: Metagenomi

Back to news